PXD032262-1

PXD032262 is an original dataset announced via ProteomeXchange.

Title	PRECLINICAL STUDIES ON CONVALESCENT HUMAN IMMUNE PLASMA DERIVED EXOSOME (ChipEXO): omics and anti-viral properties to SARS-CoV-2.
Description	The scale of the COVID-19 pandemic required the emergency development of treatment strategies. One of these strategies is the use of convalescent plasma (CP), isolated from patients recovered from a disease as a therapeutic for new patients. The use of convalescent human immune plasma derived exosomes (ChipEXO) in place of whole plasma can address issues associated with CP therapies while inducing a similar therapeutic response in recipients. Isolated exosomes would be pure of soluble protein contaminants such as coagulation factors, which can cause serious side effects such as blood clots and endothelial damage. In the light of this information, in this study, we examined the use of ChipEXO against the SARS-CoV-2 virus in terms of safety and efficacy, based on the omic analysis of ChipEXO in terms of protein and miRNA. The isolated ChipEXO was characterized according to the criteria determined by the MISEV commission. To elucidate the molecular mechanism of the exosome's activity, proteomic and miRNA analyzes were made and its content was clarified. After performing the ontological and orthological analyzes, the safety of ChipEXO for tissue and organism has been studied on both in vitro cell culture and in vivo animals. ChipEXO, which did not cause any toxic effects, was this time examined for its efficacy to examine the possible effects it may develop against SARS-CoV-2. With the guidance of the results obtained as a result of the studies, it has been revealed that ChipEXO has an effect that provides both anti-viral and tissue protection against the virus. In addition to these data, we encounter a picture in which the cytokine storm is suppressed and the complement system is modulated, and tissue homeostasis is provided in the detail of the molecular mechanism in which its anti-viral activity is discussed. With detailed pre-clinical and clinical studies to be done, ChipEXO is a promising drug candidate with high efficacy against SARS-CoV-2 therapy.
HostingRepository	PRIDE
AnnounceDate	2022-03-22
AnnouncementXML	Submission_2022-03-22_09:47:26.894.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Batuhan Bozkurt
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2022-03-14 09:10:58	ID requested
⏵ 1	2022-03-22 09:47:27	announced

Dataset with its publication pending

submitter keyword: Exosome, Extracellular Vesicles, Convalescent plasma, SARS-CoV-2.

Pakize Neslihan Taşlı
contact affiliation	Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University
contact email	pneslihan.tasli@yeditepe.edu.tr
lab head
Batuhan Bozkurt
contact affiliation	Yeditepe University
contact email	batuhanturhan.bozkurt@std.yeditepe.edu.tr
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD032262

PRIDE project URI

• PRIDE
  1. PXD032262
     1. Label: PRIDE project
     2. Name: PRECLINICAL STUDIES ON CONVALESCENT HUMAN IMMUNE PLASMA DERIVED EXOSOME (ChipEXO): omics and anti-viral properties to SARS-CoV-2.